Chemistry: analytical and immunological testing – Involving an insoluble carrier for immobilizing immunochemicals – Carrier is organic
Reexamination Certificate
2005-07-05
2005-07-05
Ceperley, Mary E. (Department: 1641)
Chemistry: analytical and immunological testing
Involving an insoluble carrier for immobilizing immunochemicals
Carrier is organic
C435S007950, C435S188000, C435S005000, C436S525000, C436S526000, C436S533000, C436S544000, C436S545000, C436S546000, C436S811000, C436S823000, C530S391100, C530S391900, C530S402000, C530S404000, C530S405000, C530S406000, C530S413000
Reexamination Certificate
active
06913936
ABSTRACT:
A novel compound comprising an immunologically invisible polyethylene glycol copolymer is used to carry one or more immunologically reactive substances. The novel compounds may be used as part of kits for immunological assays.
REFERENCES:
patent: 4970300 (1990-11-01), Fulton et al.
patent: 5187065 (1993-02-01), Schutzer
patent: 5219564 (1993-06-01), Zalipsky et al.
patent: 5455027 (1995-10-01), Zalipsky et al.
patent: 5545698 (1996-08-01), Barany et al.
patent: WO 91 13630 (1991-09-01), None
patent: WO 97 42221 (1997-11-01), None
Zalipsky, Bioconjugate Chem. (1995), vol. 6, 150-165.
Buckmann, Makromol. Chem. (1981) vol. 182: 1379-1384.
Zalipsky et al, J. Macromol. Sci.-Chem., A21 (6 & 7): 839-845 (1984).
Geckeler, Polym. Bull. (1979) vol. 1: 427-431 (1979).
Zalipsky et al, Eur. Polym. J. (1983) vol. 19: 1177-1183.
Bar, Fritz W., et al., “New Biocompatible Polymer Surface Coating for Stents Results in a Low Neointimal Response,”J. Biomedical Materials Research2000; 52: 193-198.
Becker, Timothy A., “Calcium Alginate Gel: A Biocompatible and Mechanically Stable Polymer for Endovascular Embolization,”J. Biomedical Materials Research2001; 54:76-86.
Buchko, Christopher J. et al., “Surface Characterization of Porous, Biocompatible Protein Polymer Thin Films,”Biomaterials2001; 22:1289-1300.
Buron, F., et al., “BOP: Biocompatible Osteoconductive Polymer: An Experimental Approach,”Clinical Materials1994; 16:217-221.
Ershov, I.A., et al., “Polymer Biocompatible X-Ray Contract Hydrogel for Esophageal Vein Obstruction in Portal Hypertension,”Med. Tekh.1994; 2:37-40. (Russian. See translation of Findings attached to article.)
Haisch, A., et al., “Tissue Engineering of Human Cartilage for Reconstructive Surgery Using Biocompatible, Resorbable Fibrin Glue with Polymer Structures,”HNO1996; 44:624-629. (German. English abstract on p. 625.)
Isobe, Masatsugu et al., “Bone Morphogenetic Protein Encapsulated with a Biodegradable and Biocompatible Polymer,”Journal of Biomedical Materials Research1996; 32:433-438.
Iwasaki, Yasuhiko et al., “Semi-interpenetrating Polymer Networks composed of Biocompatible Phospholipid Polymer and Segmented Polyurethane,”Journal of Biomedical Materials Research2000; 52:701-708.
Langer, R., “Biomaterials in Drug Delivery and Tissue Engineering: One Laboratory's Experience”Accounts of Chemical Research. Nov. 2, 2000; 33:94-101.
Langer, R., “Tissue Engineering,”Molecular TherapyJanuary 2000; 1:12-15.
Polous, Y. M., et al., “The Application of the Biocompatible Antimicrobic Polymer Film for the Prevention of Intestinal Suture Incompetence Under Conditions of Peritonitis,”Vest. Khir. Im. II Grek1985; 134:55-57. (Greek. English abstract on p. 57.)
Qiu, Bo et al., “Selection of Continuous Epitope Sequences and Their Incorporation into Poly(Ethylene Glycol)-Peptide Conjugates for Use in Serodiagnostic Immunoassays: Application to Lyme Disease,”Biopolymers2000; 55:319-333.
Raudino, Antonio et al., “Binding of Lipid Vesicles to Protein-Coated Solid Polymer Surfaces: A Model for Cell Adhesion to Artificial Biocompatible Materials,”Journal of Colloid and Interface Science2000; 231:66-73.
Barbour, “The Biological and Social Phenomenon of Lyme Disease”, 260 Science 1610 (1993).
Brunner, “Immune Complexes from Serum of Patients with Lyme Disease Contain Borrelia burgdorferi Antigen and Antigen-Specific Antibodies: Potential Use for Improved Testing”, 182 J. of Infectious Diseases 534 (2000).
Brunner, “Immunoglobulin M Capture Assay for Serologic Confirmation of Early Lyme Disease: Analysis of Immune Complexes with Biotinylated burgdorferi Sonicate Enhanced with Flagellin Peptide Epitope”, 36 J. Clin. Micro. 1074 (1998).
Brunner, “New Method for Detection of Borrelia burgdorferi Antigen Complexed to Antibody in Seronegatively Lyme Disease”, 249 J. Immunol. Methods 185 (2001).
Brunner, “Use of Serum Immune Complexes in a New Test that Accurately Confirms Early Lyme Disease and Active Infection with Borrelia burgdorferi”, 39 J. Clin. Microbiol. 3213 (2001).
Ervin, “The Bell Tolls for the Infectious Diseases Clinician”, 153 J. Inf. Dis. 183 (1986).
Frank, “Spot Synthesis: An Easy Technique for the Positionally Addressable, Parallel Chemical Synthesis on a Membrane Support”, 48 Tetrahedron 9217 (1992).
Geysen, “Use of Peptide Synthesis to Probe Viral Antigens for Epitopes to a Resolution of a Single Amino Acid”, 81 Proc. Natl. Acad. Sci. 3998 (1984).
Gilmore, “Outer Surface Protein C (OspC), but not p39, is a Protective Immunogen Against a Tick-Transmitted Borrelia burgdorferi Challenge: Evidence for a Conformational Protective Epitope in OspC”, 64 Infection and Immunity 2234 (1996).
Jungblut, “Proteomics in Human Disease: Cancer, Heart and Infectious Diseases”, 20 Electrophoresis 2100 (1999).
Magnarelli, “Cross Reactivity of Nonspecific Treponormal Antibody in Serologic Tests for Lyme Disease”, 28 J. Clin. Microbiol. 1276 (1990).
Mathiesen, “The Dominant Epitope of Borrelia garinii Outer Surface Protein C Recognized by Sera from Patients with Neuroborreliosis Has a Surface-Exposed Conserved Structural in Motif”, 66 Inf. And Immun. 4073 (1998).
Mathiesen, “Peptide Based OspC Enzyme Linked Immunosorbent Assay for Serodiagnosis of Lyme Borreliosis”, 36 J. Clin. Microbiol. 3474 (1998).
Qiu, “Studies on Polymers for Biomedical Applications: . . . ”, (Dissertation, Oct. 1999) (unpublished).
Schneider, “Prognostic B-Cell Epitopes on the Flagellar Protein of Borrelia burgdorferi”, 60 Inf and Immun. 316 (1992).
Sigal, “The Lyme Disease Controversy”, 156 Arch. Intem. Med 1493 (1996).
Sigal, “Pitfalls in the Diagnosis and Management of Lyme Disease”, 41 Arthritis & Rheumatism 195 (1998).
Sigal, “The Polymerase Chain Reacton Assay for Borrelia burgdorferi in the Diagnosis of Lyme Disease”, 120 Annals Intern. Med. 520 (1994).
Sigal, “A Vaccine Consisting of Recombination Borrelia burgdorferi Outer-Surface Protein A to Prevent Lyme Disease”, 4339 New Engl. J. Med. 216 (1998).
Simpson, “Antibody to a 39-Kilodalton Borrelia burgdorferi Antigen (P39) as a Marker for Infection in Experimentally and Naturally Inoculated Animals”, 29 J. Clin. Microbiol. 236 (1991).
Simpson, “Nucleotide Sequence and Analysis of the Gene in Borrelia burgdorferi encoding the immunogenic P39 Antigen”, 119 Fed. of Europ. Microbiol. Soc. Letters 381 (1994).
Simpson, “Reactivity of Human Lyme Borrealiosis Sera with a 39-Kilodalton Antigen Specific to Borrelia burgdorferi”, 28 J. Clin. Microbiol. 1329 (1990).
Yu, “Multi-Well Eliza Based on Independent Peptide Antigens for Antibody Capture”, 198 J. Immunol. Meth. 25 (1996).
Yu, “Presentation of Peptide as Albumin Conjugates for Use in Detection of Serum Antibodies by Enzyme-Linked Immunosorbent Assay”, 7 Bioconjugate Chem. 338 (1996).
Brunner Michael
Katz Michael
Qiu Bo
Sigal Leonard H
Stein Stanley
Ceperley Mary E.
University of Medicine and Dentistry of New Jersey
LandOfFree
Immunological test kit comprising an immunologically... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Immunological test kit comprising an immunologically..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Immunological test kit comprising an immunologically... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3374648